7 results
Parenteral Antimicrobial Treatment of Common Microorganisms Causing Native Vertebral Osteomyelitis - IDSA 
Staphylococci, oxacillin susceptible
Staphylococci, oxacillin
resistant Pseudomonas aeruginosa ... Parenteral #IV #Antibiotics ... Osteomyelitis #management ... #treatment #pharmacology ... #idsa
Outpatient Treatment of with Community-Acquired Pneumonia (CAP)
No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa:
or Pseudomonas aeruginosa ... fluoroquinolone #IDSA ... Acquired #Pneumonia #Antibiotics ... #Management #Guidelines ... #pharmacology
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... Guidelines - Table ... infection Episode #Pharmacology ... #Management #CDiff ... IDSA2017 #Adjunct #Antibiotics
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... mucoadhesive buccal tablet ... chew, or crush tablet ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
IDSA Recommendations ... with ARV (see Table ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Please refer to the table ... Tuberculosis #TB #IDSA ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
IDSA Recommendations ... please refer to Table ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology